Revenue: As of FY2026 Q1, the actual value is USD 2.83 M, beating the estimate of USD 333.33 K.EPS: As of FY2026 Q1, the actual value is USD -2.21, beating the estimate of USD -2.25.<h4>Financial Performance for the Three Months Ended March 31, 2026</h4><ul><li>Revenue from customers: Aligos Therapeutics, Inc. reported $2,830 thousand in revenue for the three months ended March 31, 2026, compared to $311 thousand for the same period in 2025.</li><li>Net Loss: The company reported a net loss of - $23,040 thousand for the three months ended March 31, 2026, which is a decrease from a net income of $43,088 thousand for the same period in 2025.</li><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses increased to $23,352 thousand in Q1 2026 from $14,502 thousand in Q1 2025, primarily due to increased third-party expenses for the pevifoscorvir sodium Phase 2 clinical trial. R&amp;D stock-based compensation was $700 thousand in Q1 2026, up from $500 thousand in Q1 2025.</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses were $6,407 thousand in Q1 2026, compared to $5,052 thousand in Q1 2025. The decrease in G&amp;A for the comparative period was primarily due to a decrease in legal and other related expenses. G&amp;A stock-based compensation was $600 thousand in Q1 2026, up from $400 thousand in Q1 2025.</li><li>Interest and Other Income, Net: The company recorded $811 thousand in net interest and other income for Q1 2026, a slight decrease from $880 thousand in Q1 2025.</li><li>Change in Fair Value of Warrants: Income from the change in fair value of 2023 common warrants was $3,395 thousand in Q1 2026, significantly lower than the $61,494 thousand recorded in Q1 2025.</li><li>Total Operating Expenses: Total operating expenses were $29,759 thousand in Q1 2026, up from $19,554 thousand in Q1 2025.</li><li>Loss from Operations: Loss from operations was - $26,929 thousand in Q1 2026, compared to - $19,243 thousand in Q1 2025.</li><li>Income Tax Provision: The income tax provision was - $317 thousand in Q1 2026, compared to - $43 thousand in Q1 2025.</li></ul><h4>Balance Sheet Highlights</h4><ul><li>Cash, Cash Equivalents, and Investments: As of March 31, 2026, cash, cash equivalents, and investments totaled $54.9 million, down from $77.8 million as of December 31, 2025. Specifically, cash and cash equivalents were $29,980 thousand, and short-term investments were $24,929 thousand as of March 31, 2026.</li><li>Total Assets: Total assets were $64,558 thousand as of March 31, 2026, compared to $88,533 thousand as of December 31, 2025.</li><li>Total Liabilities: Total liabilities were $32,769 thousand as of March 31, 2026, down from $34,988 thousand as of December 31, 2025.</li><li>Total Stockholders’ Equity: Total stockholders’ equity was $31,789 thousand as of March 31, 2026, compared to $53,545 thousand as of December 31, 2025.</li></ul><h4>Operational Metrics and Business Progress</h4><ul><li>Pevifoscorvir sodium: This drug candidate received Fast Track Designation from the U.S. FDA for chronic HBV infection. The Phase 2 B-SUPREME study is ongoing, with 74 participants enrolled in the HBeAg- cohort (Part 2a) and 103 in the HBeAg+ cohort (Part 1a) as of April 2026. A first interim analysis for the HBeAg- cohort indicated that futility criteria were not met, and the DSMB recommended increasing the sample size of Part 2a from 74 to 100 participants.</li><li>Partnership: Aligos Therapeutics, Inc. entered into an exclusive license deal with Xiamen Amoytop Biotech Co., Ltd. (Amoytop) for pevifoscorvir sodium in Greater China, including a $25 million upfront payment and up to $420 million in potential milestones plus royalties.</li><li>ALG-170675: This antisense oligonucleotide (ASO) for chronic HBV infection has begun IND-enabling studies, with Amoytop funding development costs in China.</li><li>ALG-055009: Evaluation of funding options, including potential out-licensing, is ongoing for this THR-β agonist for obesity and MASH.</li></ul><h4>Outlook / Guidance</h4>Aligos Therapeutics, Inc. expects its cash, cash equivalents, and investments to provide sufficient funding for planned operations into the fourth quarter of 2026, including the anticipated $25 million upfront payment from the Amoytop deal. A second interim analysis for the HBeAg+ cohort of the B-SUPREME study is anticipated in the second half of 2026, with topline data for both HBeAg- and HBeAg+ cohorts expected in 2027.

Aligos Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 2.83 M